



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Habener, Joel F.

Appl. No. 09/635,679

Filed: August 10, 2000

For: **Insulinotropic Hormone and Uses
Thereof** (*as amended*)

Confirmation No.: 6862

Art Unit: 1645

Examiner: Minnifield, Nita M.

Atty. Docket: 0609.1090009/MAC/ALS

Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED

DEC 04 2003

TECH CENTER 1600/2900

Sir:

In reply to the Office Action dated May 23, 2003, Applicant submits the following
Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by
presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are
required beyond those that may otherwise be provided for in documents accompanying

this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.